Adlai Goldberg, EY

Industrialized collaboration is critical to taking next-generation cell and gene therapies to the next level—if companies can build on pandemic-partnering momentum

The importance of thinking strategically about the infrastructure and foresight needed to scale up CGTs—not as treatments of last resort, but first choice